89bio, Inc. announced on January 13, 2025, that it had completed enrollment in its Phase 3 ENTRUST trial for patients with severe hypertriglyceridemia (SHTG). Topline 26-week data from this trial are expected in the second half of 2025, marking a critical upcoming catalyst for the company.
The company also confirmed that its Phase 3 ENLIGHTEN program, which includes trials for non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH), continues to enroll patients across both studies. These trials are pivotal for the potential approval of pegozafermin.
Financially, 89bio reported a strong cash position, with cash, cash equivalents, and marketable securities totaling approximately $440 million as of December 31, 2024. This capital is essential to fund the ongoing and future clinical development of pegozafermin.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.